The market performance of Inhibikase Therapeutics Inc has been somewhat stable. Over the past year, the company’s stock achieved a high of $3.82 on 01/25/24, with the lowest value for the same timeframe being $0.79, recorded on 10/10/23.
52-week price history of IKT Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. Inhibikase Therapeutics Inc’s current trading price is -60.21% away from its 52-week high, while its distance from the 52-week low is 92.41%. The stock’s price range during this period has fluctuated between $0.79 and $3.82. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 15.49 million for the day, which was evidently higher than the average daily volume of 21830.0 over the last three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Financial Performance and Market Capitalization
Inhibikase Therapeutics Inc (IKT) has experienced a quarterly rise of 11.76% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 11.34M and boasts a workforce of 8 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.4198, with a change in price of -0.1700. Similarly, Inhibikase Therapeutics Inc recorded 175,234 in trading volume during the last 100 days, posting a change of -9.66%.
IKT Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for IKT stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.01.
IKT Stock Stochastic Average
Inhibikase Therapeutics Inc’s raw stochastic average for the past 50 days is currently at 61.84%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 61.84%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 39.32% and 35.30%, respectively.
IKT Stock Price Performance Analysis
Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. Year to date metric has recorded a gain of 19.69%.However, over the last six months, we can see a stronger performance of -29.30%. Over the last 30 days, the price of IKT has fallen by 13.43%. And in the last five days, it has surged by 26.67%.
